Author:
Villanueva Jessie,Vultur Adina,Lee John T.,Somasundaram Rajasekharan,Fukunaga-Kalabis Mizuho,Cipolla Angela K.,Wubbenhorst Bradley,Xu Xiaowei,Gimotty Phyllis A.,Kee Damien,Santiago-Walker Ademi E.,Letrero Richard,D'Andrea Kurt,Pushparajan Anitha,Hayden James E.,Brown Kimberly Dahlman,Laquerre Sylvie,McArthur Grant A.,Sosman Jeffrey A.,Nathanson Katherine L.,Herlyn Meenhard
Subject
Cancer Research,Cell Biology,Oncology
Reference44 articles.
1. Altekruse, S.F., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Ruhl, J., Howlader, N., Tatalovich, Z., Cho, H., Mariotto, A., et al. (2010). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. http://seercancergov/csr/1975_2007/.
2. Mcl-1 is required for melanoma cell resistance to anoikis;Boisvert-Adamo;Mol. Cancer Res.,2009
3. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma;Bollag;Nature,2010
4. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer;Carracedo;J. Clin. Invest.,2008
5. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance;Casa;Front. Biosci.,2008
Cited by
1070 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献